4.7 Article

Deep Learning Electrocardiographic Analysis for Detection of Left-Sided Valvular Heart Disease

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2022.05.029

关键词

aortic regurgitation; aortic stenosis; artificial intelligence; deep learning; mitral regurgitation; valvular heart disease

资金

  1. National Institutes of Health [2T32HL007854-21]
  2. National Institutes of Health/National Heart, Lung, and Blood Institute Award [R01HL148248]
  3. Pfizer
  4. Eidos Therapeutics
  5. Google
  6. Edwards LifeSciences
  7. Amyloidosis Foundation
  8. Glorney-Raisbeck Fellowship Award from the New York Academy of Medicine
  9. Abbott Structural
  10. Boston Scientific
  11. Gore and Associates
  12. General Electric
  13. Janssen Pharmaceuticals
  14. Myokardia
  15. Medtronic
  16. Abbott Vascular
  17. JenaValve
  18. Attralus
  19. Canon Medical Systems
  20. GE Healthcare
  21. Roche Medical Systems
  22. W. L. Gore and Associates
  23. XyloCor Therapeutics
  24. Abbott
  25. Edwards

向作者/读者索取更多资源

This study developed ECG deep learning algorithms to accurately identify aortic stenosis, aortic regurgitation, and mitral regurgitation. The algorithms performed well in validation and modeling, and may serve as the basis for a valvular heart disease screening program.
BACKGROUND Valvular heart disease is an important contributor to cardiovascular morbidity and mortality and re-mains underdiagnosed. Deep learning analysis of electrocardiography (ECG) may be useful in detecting aortic stenosis (AS), aortic regurgitation (AR), and mitral regurgitation (MR). OBJECTIVES This study aimed to develop ECG deep learning algorithms to identify moderate or severe AS, AR, and MR alone and in combination. METHODS A total of 77,163 patients undergoing ECG within 1 year before echocardiography from 2005-2021 were identified and split into train (n = 43,165), validation (n = 12,950), and test sets (n = 21,048; 7.8% with any of AS, AR, or MR). Model performance was assessed using area under the receiver-operating characteristic (AU-ROC) and precision -recall curves. Outside validation was conducted on an independent data set. Test accuracy was modeled using different disease prevalence levels to simulate screening efficacy using the deep learning model. RESULTS The deep learning algorithm model accuracy was as follows: AS (AU-ROC: 0.88), AR (AU-ROC: 0.77), MR (AU -ROC: 0.83), and any of AS, AR, or MR (AU-ROC: 0.84; sensitivity 78%, specificity 73%) with similar accuracy in external validation. In screening program modeling, test characteristics were dependent on underlying prevalence and selected sensitivity levels. At a prevalence of 7.8%, the positive and negative predictive values were 20% and 97.6%, respectively. CONCLUSIONS Deep learning analysis of the ECG can accurately detect AS, AR, and MR in this multicenter cohort and may serve as the basis for the development of a valvular heart disease screening program. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据